pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2016-26-3-323-327pulmo-722Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESОпыт применения селективного ингибитора фосфодиэстеразы-4 рофлумиласта (Даксас) у пациентов с хронической обструктивной болезнью легких и метаболическим синдромомAn experience of therapy of patients with chronic obstructive pulmonary disease and metabolic syndrome with selective phosphodiesterase-4 inhibitor roflumilastИгнатоваГ. Л.IgnatovaG. L.

д. м. н., профессор, заведующая кафедрой терапии ФДПО ГБОУ ВПО «ЮжноУральский государственный медицинский университет» Минздрава России; тел.: (351) 7426640

MD, Professor, Head of Department of Therapy, Faculty of Postgraduate Physician Training, South Ural State Medical University, Healthcare Ministry of Russia; tel.: (351) 7426640

iglign@mail.ruБлиноваЕ. В.BlinovaE. V.

к. м. н., ассистент кафедры терапии ФДПО ГБОУ ВПО «ЮжноУральский государственный медицинский университет» Минздрава России; тел.: (351) 7428257

PhD, Assistant Lecturer at Department of Therapy, Faculty of Postgraduate Physician Training, South Ural State Medical University, Healthcare Ministry of Russia; tel.: (351) 7428257

blinel@mail.ruБельснерМ. С.Bel'snerM. S.

аспирант кафедры терапии ФДПО ГБОУ ВПО «ЮжноУральский государственный медицинский университет» Минздрава России; тел.: (351) 7428257

PhD student at Department of Therapy, Faculty of Postgraduate Physician Training, South Ural State Medical University, Healthcare Ministry of Russia; tel.: (351) 7428257

mariika_04@mail.ruГребневаИ. В.GrebnevaI. V.

к. м. н., доцент кафедры терапии ФДПО ГБОУ ВПО «ЮжноУральский государственный медицинский университет» Минздрава России; тел.: (351) 7428257

PhD, Associate Professor at Department of Therapy, Faculty of Postgraduate Physician Training, South Ural State Medical University, Healthcare Ministry of Russia; tel.: (351) 7428257

grebneviv@mail.ruГБОУ ВПО «Южно&Уральский государственный медицинский университет» Минздрава России: 454096, Челябинск, ул. Воровского, 64РоссияSouth Ural State Medical University, Healthcare Ministry of Russia: 64, Vorovskogo str., Chelyabinsk, 454092, RussiaRussian Federation201627072016263323327Copyright © Игнатова Г.Л., Блинова Е.В., Бельснер М.С., Гребнева И.В., 20162016Игнатова Г.Л., Блинова Е.В., Бельснер М.С., Гребнева И.В.Ignatova G.L., Blinova E.V., Bel'sner M.S., Grebneva I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/722Цель

Цель. Изучение эффективности и безопасности применения препарата рофлумиласт (Даксас) в дозе 500 мг в сутки у больных хронической обструктивной болезнью легких (ХОБЛ) и метаболическим синдромом (МС) в дополнение к базисной терапии.

Материалы и методы

Материалы и методы. В Городском консультативно-диагностическом центре для больных пульмонологического профиля при ГБУЗ «Областная клиническая больница № 4» (Челябинск) проведено комплексное клинико"функциональное исследование среди пациентов мужского пола (n = 42) с ХОБЛ III–IV степени в сочетании с МС и частыми обострениями ХОБЛ (≥ 2 раз в год).

Результаты

Результаты. Применение рофлумиласта у пациентов с ХОБЛ и МС сопровождается улучшением клинических, лабораторных и функциональных показателей и снижением частоты обострений ХОБЛ.

The aim of this study was to evaluate clinical efficacy and safety of selective phosphodiesterase"4 inhibitor roflumilast in patients with COPD and metabolic syndrome.

Methods

Methods. In this prospective study, patients with stage III – IV COPD, frequent exacerbation phenotype (≥ 2 per a year) and metabolic syndrome (n = 42) were treated with roflumilast (Daxas) 500 mg q.d. additionally to the basic therapy for 12 months. Clinical investigation, mMRC scale and CAT questionnaire, pulse oxymetry, spirometry, 6"min walking test, measurement of glucose, lipids and C"reactive protein in blood were used in all patients.

Results

Results. Exacerbation rate decreased in patients with COPD treated with roflumilast. FEV1 and quality of life improved in patients treated with roflumilast. Therapy with roflumilast was associated with statistically significant reduction in the waist circumference without significant change in the body weight, waist"to"hip ratio or body mass index.

Conclusion

Conclusion. Therapy with roflumilast was associated with improvement in clinical, laboratory and functional parameters and reduction in exacerbation rate in patients with COPD and metabolic syndrome.

хроническая обструктивная болезнь легкихметаболический синдромобострениярофлумиластchronic obstructive pulmonary diseasemetabolic syndromeexacerbationroflumilastReferencesФедеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М.: РРО; 2013.Federal Clinical Guidelines on Diagnosis and Management of Chronic Obstructive Pulmonary Disease. Moscow: RRO, 2013 (in Russian).Fabbri L.M., Luppi F., Beghe B., Rabe K.F. Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31: 2014–2012.Fabbri L.M., Luppi F., Beghe B., Rabe K.F. Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31: 2014–2012.Loscalzo J. System’s biology and personalized medicine: a network approach to human disease. Proc. Am. Thorac. Soc. 2011; 8: 196–198.Loscalzo J. System’s biology and personalized medicine: a network approach to human disease. Proc. Am. Thorac. Soc. 2011; 8: 196–198.Thomsen M., Dahl M., Lange P. et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186: 982–988.Thomsen M., Dahl M., Lange P. et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186: 982–988.http://www.who.int/respiratory/copd/burden/en/index.htmlhttp://www.who.int/respiratory/copd/burden/en/index.htmlSin D.D., Man S.F. Why are patients with COPD at increased risk of cardiovascular diseases? Circulation. 2003; 107 (11): 1514–1519.Sin D.D., Man S.F. Why are patients with COPD at increased risk of cardiovascular diseases? Circulation. 2003; 107 (11): 1514–1519.Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Русский медицинский журнал. 2008; 2: 58–64.Chuchalin A.G. Chronic obstructive pulmonary disease and comorbidity. Russkiy meditsinskiy zhurnal. 2008; 2: 58–64 (in Russian).Chung K.F. Inflammatory mediators in chronic obstructive pulmonary disease. Curr. Drug Targets Inflamm. Allergy. 2005; 4 (6): 619–625.Chung K.F. Inflammatory mediators in chronic obstructive pulmonary disease. Curr. Drug Targets Inflamm. Allergy. 2005; 4 (6): 619–625.Pinto"Plata V.M., Mullerova H., Toso J.F. et al. C"reactive protein in patients with COPD, control smokers and nonsmokers. Thorax. 2006; 61: 23–28.Pinto"Plata V.M., Mullerova H., Toso J.F. et al. C"reactive protein in patients with COPD, control smokers and nonsmokers. Thorax. 2006; 61: 23–28.Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. The association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax. 2004; 59: 574–580.Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. The association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax. 2004; 59: 574–580.Hole D.J., Watt G.C., Davey"Smith G. et al. Impaired lung function and mortality risk in men and women: findings from Renfrew and Paisley prospective population study. Br. Med. J. 1996; 313: 711–775.Hole D.J., Watt G.C., Davey"Smith G. et al. Impaired lung function and mortality risk in men and women: findings from Renfrew and Paisley prospective population study. Br. Med. J. 1996; 313: 711–775.Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am. J. Crit. Care Med. 2002; 166: 333–339.Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am. J. Crit. Care Med. 2002; 166: 333–339.Sin D.D., Wu. L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population"based study and a systematic review of the literature. Chest. 2005; 127: 1952–1959.Sin D.D., Wu. L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population"based study and a systematic review of the literature. Chest. 2005; 127: 1952–1959.Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994; 272: 1497–1505.Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994; 272: 1497–1505.Heindl S., Lehnert M., Criee C.P. et al. Marked sympathetic activation in patients with chronic respiratory failure. Am. J. Respir. Crit. Care Med. 2001; 164: 597–601.Heindl S., Lehnert M., Criee C.P. et al. Marked sympathetic activation in patients with chronic respiratory failure. Am. J. Respir. Crit. Care Med. 2001; 164: 597–601.Verma S., Li S.H., Badiwala M.V. et al. Endothelin antagonism and interleukin"6 inhibition attenuate the proatherogenoc effects of C"reactive protein. Circulation. 2002; 105: 1890–1896.Verma S., Li S.H., Badiwala M.V. et al. Endothelin antagonism and interleukin"6 inhibition attenuate the proatherogenoc effects of C"reactive protein. Circulation. 2002; 105: 1890–1896.Wellen K.E., Hotamisligil G.S. Inflamation, stress and diabetes. J. Clin. Invest. 2005; 115: 1111–1119.Wellen K.E., Hotamisligil G.S. Inflamation, stress and diabetes. J. Clin. Invest. 2005; 115: 1111–1119.Boswell"Smith V., Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD"focus on roflumilast. Int. J. Chron. Obstruct. Pulm. Dis. 2007; 2 (2): 121–129.Boswell"Smith V., Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD"focus on roflumilast. Int. J. Chron. Obstruct. Pulm. Dis. 2007; 2 (2): 121–129.

The authors declare that there are no conflicts of interest present.